Overview

Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs

Status:
Completed
Trial end date:
2018-10-25
Target enrollment:
Participant gender:
Summary
Phase IV 3-Way Double-blind, Randomized, Crossover Study to Compare the Awakening Threshold Effects (responsivity) of Belsomra 10 mg and 20 mg to Placebo in non-elderly Insomniacs
Phase:
Phase 4
Details
Lead Sponsor:
Henry Ford Health System
Treatments:
Suvorexant